Clinical Trials Browser

Recruiting × Interventional × Neoplasm, Residual × Clear all

NCT04521231 2026-04-16

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07069595 2026-04-13

PREDICT-RD

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT07136077 2026-04-06

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07134088 2026-03-30

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Phase 1/2 Recruiting

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT05232916 2026-03-19

FLAMINGO-01

Phase 3 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT06500273 2026-03-18

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

Pathologic Complete Response, Neoplasm, Residual

NCT07441291 2026-02-27

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

Phase 3 Recruiting

Neoplasm, Residual

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT06693830 2026-01-23

ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Phase NA Recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06358430 2026-01-15

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

Phase 1 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Recruiting

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT05929222 2025-12-24

FIL_GAZEBO

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Neoplasm, Residual

NCT07280494 2025-12-12

S101MRD

Phase 1 Recruiting

Lymphoma, Neoplasm, Residual

NCT07178847 2025-12-01

NeckTAR-IN

Phase NA Recruiting

Neoplasm, Residual

NCT04707300 2025-11-20

HTLP-ONCO

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT03326921 2025-11-14

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Phase EARLY_PHASE1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06828991 2025-10-20

GOLD

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT01898039 2025-10-02

Modified Vaccine for High Risk or Low Residual Melanoma Patients

Phase 1/2 Recruiting

Melanoma, Neoplasm, Residual

NCT06668558 2025-09-19

VERDI

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06993675 2025-08-29

ROTATE

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07021677 2025-06-15

DARA_T_ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06414148 2025-06-05

EpLCART

Phase 2 Recruiting

Lymphoma, Recurrence, Neoplasm, Residual

NCT07003737 2025-06-04

Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation

Phase NA Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06718244 2025-05-23

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06930807 2025-04-16

Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT06885476 2025-03-20

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06886074 2025-03-20

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05904106 2024-12-02

VINCENT

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05534087 2024-11-29

CLAUDIA

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Phase NA Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT05965479 2024-11-12

DECIPHER

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Neoplasm, Residual

NCT06608732 2024-11-05

Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

Phase 2 Recruiting

Burkitt Lymphoma, Neoplasm, Residual

NCT06498752 2024-08-06

MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Neoplasm, Residual

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06301425 2024-07-10

MRD Response-adapted Allo-HSCT for Adverse-risk AML

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06253650 2024-06-13

TRINITY

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms, Neoplasm, Residual

NCT06158269 2023-12-06

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT06066905 2023-10-27

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Phase NA Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05623267 2023-08-07

SURPASS

Phase 2/3 Recruiting

Neoplasm, Residual